BP
TMCI icon

Ballentine Partners’s Treace Medical Concepts TMCI Stock Holding History

Ballentine Partners’s Portfolio TMCI Stock Details TMCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-21,148
Closed -$177K – 1063
2025
Q1 		$177K Sell
21,148
-3,861
-15% -$34.7K ﹤0.01% 821
2024
Q4 		$186K Buy
25,009
+2,314
+10% +$15.5K ﹤0.01% 797
2024
Q3 		$132K Buy
+22,695
New +$146K ﹤0.01% 784

Other funds holding TMCI

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GS
Gagnon Securities New York $433M AUM 29.08% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
CIBC Private Wealth Group
CIBC Private Wealth Group Atlanta, Georgia $59.2B AUM 20.62% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Ballentine Partners's TMCI Position: Q2 2025 in Review

Ballentine Partners sold out of Treace Medical Concepts (TMCI) in Q2 2025, closing a stake of 21,148 shares — an estimated $177K sold.

Ballentine Partners first reported a position in TMCI in Q3 2024 and held it in 3 quarters. The position peaked at $186K in Q4 2024. 125 funds tracked by Wall St. Rank hold TMCI as of Q2 2025.

  • Ballentine Partners reported no remaining Treace Medical Concepts position as of Q2 2025 after selling out during the quarter.
  • Ballentine Partners sold 21,148 Treace Medical Concepts shares in Q2 2025, an estimated $177K.
  • Ballentine Partners first reported a position in Treace Medical Concepts in Q3 2024 and held it in 3 quarters.
  • Ballentine Partners's Treace Medical Concepts position peaked at $186K in Q4 2024.
  • 125 funds tracked by Wall St. Rank held Treace Medical Concepts as of Q2 2025.

Based on Ballentine Partners's 13F filing for Q2 2025, filed 15 Jul 2025.